Olaratumab

Olaratumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	PDGF-R α
Clinical data
Trade names	Lartruvo
Other names	IMC-3G3, LY-3012207
AHFS/Drugs.com	Monograph
License data	US DailyMed: Lartruvo;
Routes of; administration	Intravenous infusion
ATC code	L01FX10 (WHO) ;
Legal status
Legal status	CA: ℞-only; UK: POM (Prescription only); US: ℞-only;
Pharmacokinetic data
Protein binding	None
Metabolism	Proteolytic enzymes
Elimination half-life	11 days
Identifiers
CAS Number	1024603-93-7 ;
DrugBank	DB06043 ;
ChemSpider	None;
UNII	TT6HN20MVF;
KEGG	D09939 ;
Chemical and physical data
Formula	C6554H10076N1736O2048S40
Molar mass	147241.21 g·mol−1
	(what is this?) (verify)

Olaratumab, sold under the brand name Lartruvo, is a monoclonal antibody medication developed by Eli Lilly and Company for the treatment of solid tumors. It is directed against the platelet-derived growth factor receptor alpha.^[2]

It was removed from the United States and European Union markets in 2019, due to insufficient proof of its medical advantage (see below "Medical uses").

^ "Cancer therapies". Health Canada. 8 May 2018. Retrieved 13 April 2024.
^ "Statement on a Nonproprietary name adopted by the USAN Council: Olaratumab" (PDF). Archived from the original (PDF) on 15 August 2016. Retrieved 18 March 2010.

[1] "Cancer therapies". Health Canada. 8 May 2018. Retrieved 13 April 2024.

[2] "Statement on a Nonproprietary name adopted by the USAN Council: Olaratumab" (PDF). Archived from the original (PDF) on 15 August 2016. Retrieved 18 March 2010.

[1]

[2]